Abstract

The administration of intranasal insulin improves symptoms related to Alzheimer’s disease. The research was conducted through a hypothesis-based review, such as, PubMed, DynaMed, and EBSCOhost. The articles published between 2011 and 2020 were included. The studies included randomized controlled trials and cohort studies. The study populations included participants associated with cognitive-related conditions. The group of humans and animal models were also considered. All ten articles showed how the administration of intranasal insulin can improve the symptoms related to Alzheimer’s disease. However, these findings varied on the level of dose used, the duration of the treatment and the type of insulin formulations used. Future studies can consider to provide a more homogenous group of study population, cognitive-related activities to observe, and duration of the administration in order to provide a more credible result.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.